Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
about
Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathwayMetastasis-associated protein 1 interacts with NRIF3, an estrogen-inducible nuclear receptor coregulatorMICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functionsFunctional implications of altered subcellular localization of PELP1 in breast cancer cells.Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha).Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain.Nuclear receptor corepressor complexes in cancer: mechanism, function and regulationThe cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasionGeneral molecular biology and architecture of nuclear receptors.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRTNew insights into the functions and regulation of the transcriptional corepressors SMRT and N-CoRG protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation.Nuclear compartmentalization of N-CoR and its interactions with steroid receptors.Limiting effects of RIP140 in estrogen signaling: potential mediation of anti-estrogenic effects of retinoic acid.An abridged history of sex steroid hormone receptor action.Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members.
P2860
Q21195156-CB4C3A5E-E5C3-4226-A6F8-432DC1C26E6AQ24564251-CF72454E-BE99-4633-94BD-90F714E0C06FQ28183743-8417FBC6-DE9B-476D-BB64-D908D3A85CE9Q28270490-E92E414D-1A65-4B39-B42A-53E297C65F0AQ33270648-B79E0447-2332-4491-BF60-BDF6D3BF62DDQ33705027-D9EA223E-E383-40FD-8FC3-3910F83CF1DEQ34448240-6DCFF963-F36E-4F89-8D5C-AE4A90EAD7A6Q35070908-44F75D3D-B1E3-4918-8A61-0C1B0C2B37ECQ36797684-E9A6D86C-F68F-4653-9F67-DC8B63DB0F6BQ36860992-573B9A36-542F-4D79-A0D2-06511E89E891Q36917061-2A804012-D445-4FF8-B924-505E4C0D1EE3Q37184168-F1D91B74-FC90-4FCA-9725-0E87A84E78AFQ37479355-B9A84777-B906-426B-BA10-218AEC2BC952Q38409573-C40D0C75-9E08-4AF4-A01E-680EF890BD45Q40474832-449B90BF-A416-4760-A8E2-BF163AAD4317Q40685277-E0CBF9B5-E8C4-43FA-8990-ADFC57C772D0Q44286566-49E79FAE-8A81-4EAB-BFFC-8C6DF5981E4A
P2860
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@ast
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@en
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@nl
type
label
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@ast
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@en
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@nl
prefLabel
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@ast
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@en
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@nl
P2093
P1433
P1476
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.
@en
P2093
P304
P356
10.1016/S0039-128X(00)00116-1
P577
2000-10-01T00:00:00Z